Serge Belanger
Stock Analyst at Needham
(4.71)
# 715
Out of 4,361 analysts
1078
Total ratings
48.7%
Success rate
13.9%
Average return
Main Sectors:
Stocks Rated by Serge Belanger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Downgraded: Hold | n/a | $0.45 | - | 61 | Jun 2, 2026 | |
| MANE Veradermics | Initiated Coverage: Buy | $136 | $98.18 | +38.52% | 1 | Jun 2, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $46 → $38 | $12.29 | +209.19% | 8 | Jun 1, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $23 | $13.50 | +70.37% | 50 | May 20, 2026 | |
| KALV KalVista Pharmaceuticals | Maintained: Hold | n/a | $26.94 | - | 58 | May 15, 2026 | |
| CRMD CorMedix | Maintained: Buy | $15 | $8.17 | +83.60% | 35 | May 14, 2026 | |
| OMER Omeros | Maintained: Hold | n/a | $10.26 | - | 52 | May 14, 2026 | |
| VRCA Verrica Pharmaceuticals | Rated: Hold | n/a | $5.79 | - | 47 | May 13, 2026 | |
| ESPR Esperion Therapeutics | Maintained: Hold | n/a | $3.14 | - | 40 | May 12, 2026 | |
| COLL Collegium Pharmaceutical | Maintained: Buy | $56 | $30.48 | +83.73% | 167 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 → $30 | $17.87 | +67.88% | 23 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $70 | $55.11 | +27.02% | 71 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $18.47 | - | 43 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $78 | $52.30 | +49.14% | 39 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 | $20.79 | +73.16% | 33 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $48 | $31.74 | +51.23% | 16 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $16 | $8.34 | +91.85% | 56 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $85 → $102 | $70.91 | +43.84% | 48 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 | $15.87 | +101.64% | 34 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $8.31 | +116.61% | 13 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $6.17 | - | 29 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $32 | $22.25 | +43.82% | 78 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.3402 | - | 48 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9364 | n/a | 9 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8005 | n/a | 13 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $1.63 | n/a | 1 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0071 | n/a | 2 | Jun 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $5 | $0.076 | n/a | 3 | Aug 19, 2016 |
Heron Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.45
Upside: -
Veradermics
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $136
Current: $98.18
Upside: +38.52%
Oculis Holding AG
Jun 1, 2026
Maintained: Buy
Price Target: $46 → $38
Current: $12.29
Upside: +209.19%
Trevi Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $23
Current: $13.50
Upside: +70.37%
KalVista Pharmaceuticals
May 15, 2026
Maintained: Hold
Price Target: n/a
Current: $26.94
Upside: -
CorMedix
May 14, 2026
Maintained: Buy
Price Target: $15
Current: $8.17
Upside: +83.60%
Omeros
May 14, 2026
Maintained: Hold
Price Target: n/a
Current: $10.26
Upside: -
Verrica Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: n/a
Current: $5.79
Upside: -
Esperion Therapeutics
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $3.14
Upside: -
Collegium Pharmaceutical
May 12, 2026
Maintained: Buy
Price Target: $56
Current: $30.48
Upside: +83.73%
May 12, 2026
Rated: Buy
Price Target: $25 → $30
Current: $17.87
Upside: +67.88%
May 11, 2026
Maintained: Buy
Price Target: $54 → $70
Current: $55.11
Upside: +27.02%
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $18.47
Upside: -
May 8, 2026
Maintained: Buy
Price Target: $80 → $78
Current: $52.30
Upside: +49.14%
May 7, 2026
Maintained: Buy
Price Target: $36
Current: $20.79
Upside: +73.16%
May 7, 2026
Maintained: Buy
Price Target: $48
Current: $31.74
Upside: +51.23%
May 6, 2026
Maintained: Buy
Price Target: $18 → $16
Current: $8.34
Upside: +91.85%
May 6, 2026
Maintained: Buy
Price Target: $85 → $102
Current: $70.91
Upside: +43.84%
May 5, 2026
Maintained: Buy
Price Target: $32
Current: $15.87
Upside: +101.64%
May 5, 2026
Maintained: Buy
Price Target: $18
Current: $8.31
Upside: +116.61%
May 5, 2026
Maintained: Hold
Price Target: n/a
Current: $6.17
Upside: -
May 1, 2026
Maintained: Buy
Price Target: $30 → $32
Current: $22.25
Upside: +43.82%
Dec 23, 2025
Rated: Hold
Price Target: n/a
Current: $0.3402
Upside: -
Oct 28, 2022
Rated: Hold
Price Target: n/a
Current: $0.9364
Upside: n/a
Oct 28, 2022
Rated: Hold
Price Target: n/a
Current: $0.8005
Upside: n/a
Nov 5, 2021
Maintained: Buy
Price Target: $22
Current: $1.63
Upside: n/a
Jun 26, 2017
Reiterated: Hold
Price Target: n/a
Current: $0.0071
Upside: n/a
Aug 19, 2016
Reiterated: Buy
Price Target: $11 → $5
Current: $0.076
Upside: n/a